TMCnet News
Bone Marrow Transplant Rejection - Pipeline Review, H2 2017 - Research and MarketsThe "Bone Marrow Transplant Rejection - Pipeline Review, H2 2017" report has been added to Research and Markets' offering. Bone Marrow Transplant Rejection - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 22, 12, 47, 9 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3, 14 and 2 molecules, respectively. Bone Marrow Transplant Rejection (Immuology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Key Topics Covered:
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/research/k7lr7p/bone_marrow
View source version on businesswire.com: http://www.businesswire.com/news/home/20170913006095/en/ |
